BTK and B-cell chronic lymphocytic leukemia: Multiple clinical trials have demonstrated the safety and efficacy of ibrutinib, a first‐in‐class Bruton's tyrosine kinase (BTK) inhibitor, in the treatment of patients with chronic lymphocytic leukemia (CLL).1, 2, 3